Your AI-Trained Oncology Knowledge Connection!
Matthew S. Davids, MD, MMSc, associate director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses the use of the BCL‐2 inhibitor, venetoclax (Venclexta) with dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (R-EPOCH) to treat patients with Richter
Julia M. Vose, MD, professor and chief in the Division of Oncology/Hematology at University of Nebraska Medical Center discusses the rationale for the phase I/II trial of acalabrutinib (Calquence) plus pembrolizumab (Keytruda) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Maintenance therapy with rituximab did not lead to an improvement in disease-free survival among patients who achieved complete remission following 4 cycles of R-CHOP.
Treatment with rituximab (Rituxan) plus lenalidomide (Revlimid) followed by maintenance therapy demonstrated promising clinical activity for patients with relapsed/refractory indolent non-Hodgkin's lymphoma, according to findings from the phase IIIb MAGNIFY study.
Treatment with JCAR017 demonstrated a complete response rate of 59% and an objective response rate of 86% for patients with relapsed or refractory diffuse large B-cell lymphoma.
Chan Cheah, MD, University of Western Australia, discusses treatment for patients with nodular lymphocyte predominant Hodgkin lymphoma.
Angelo Fama, MD, Division of Hematology, Mayo Clinic, discusses a case control study of the GB Virus-C (GBV-C) infection and the risk of lymphoma.
Combining pembrolizumab with rituximab induced a high response rate in patients with relapsed follicular lymphoma.
Copanlisib showed an objective response rate of 59.2% without inducing major colitis events or elevation of hepatic transaminases in patients with relapsed or refractory indolent B-cell lymphoma.
At more than 40 months’ follow-up, combining obinutuzumab with chemotherapy in the first-line setting reduced the risk of disease progression or death by 32% versus rituximab plus chemotherapy in patients with follicular lymphoma.
Combining the novel BTK inhibitor BGB-3111 with the CD-20 antibody obinutuzumab demonstrated clinical activity and was well tolerated in patients with chronic lymphocytic leukemia/small lymphocytic leukemia or follicular lymphoma.
BGB-3111, a highly specific BTK inhibitor, is active in patients with Waldenström macroglobulinemia, according to an interim analysis from an ongoing phase I trial.
Avelumab (Bavencio) demonstrated clinical activity and an acceptable safety and tolerability profile in heavily pretreated patients with classical Hodgkin lymphoma.
Clemens A. Schmitt, MD, director and professor at Berlin School of Integrative Oncology, discusses a conceptually novel treatment approach to classical Hodgkin lymphoma.
Neil L. Berinstein, MD, professor, University of Toronto, Sunnybrook Health Sciences Centre, discusses combination treatments for patients with high-risk or recurrent follicular lymphoma.
Tazemetostat (EPZ-6438) demonstrated strong clinical activity in patients with advanced EZH2-mutated follicular lymphoma, and was also active in patients with diffuse large B-cell lymphoma.
High levels of response were observed with nivolumab (Opdivo), regardless of previous treatment with brentuximab vedotin (Adcetris), in patients with relapsed/refractory Hodgkin lymphoma after autologous stem-cell transplant.
Pembrolizumab (Keytruda) demonstrated antitumor activity in the majority of patients with recurrent/refractory primary mediastinal large B-cell lymphoma.
Loretta J. Nastoupil, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses high response rates with prembrolizumab (Keytruda) in combination with rituximab (Rituxan) in patients with relapsed follicular lymphoma.
Sattva Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; KTE-C19) for patients with refractory aggressive non-Hodgkin lymphoma.
Constantine S. Tam, MD, discusses phase III PCYC-1143 trial is investigating the combination of ibrutinib and venetoclax as well as the next steps with venetoclax /ibrutinib and other rational combinations in MCL.
Patients with refractory aggressive non-Hodgkin lymphoma lacking curative treatment options demonstrated high response rates and durable responses plus a manageable safety profile following treatment with axicabtagene ciloleucel.
Tisagenlecleucel-T (CTL019) met its primary endpoint for best objective response rate in patients with relapsed or refractory diffuse large B-cell lymphoma.
Brad S. Kahl, MD, professor, Department of Medicine, Oncology Division, Washington University School of Medicine, discusses ADCT-402 for patients with relapsed/refractory B-cell lineage non-Hodgkin lymphoma.
Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the phase II and phase III studies investigating the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).
Martin Barrett, PhD, Clinical Scientist at Hoffmann-La Roche, discusses a study which compared intravenous (IV) rituximab to subcutaneous rituximab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Infusions of CTL019 achieved durable responses and showed an acceptable safety profile in heavily pretreated patients with CD19-positive non-Hodgkin lymphoma.
A three-drug combination comprising the novel Bcl-2 inhibitor venetoclax, bortezomib, and dexamethasone demonstrated a clinical benefit in heavily pretreated patients with relapsed/refractory multiple myeloma.
Lenalidomide in combination with rituximab and as maintenance monotherapy is highly active in patients with relapsed/refractory central nervous system non-Hodgkin lymphoma.
Carolina Moreno Atanasio, MD, University of Barcelona, discusses an ongoing phase III study comparing ibrutinib and obinutuzumab with chlorambucil and obinutuzumab in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
